Repatha with Ongoing Care
Repatha blocks PCSK9 so the liver can remove more LDL cholesterol from the blood. Alongside its LDL-lowering indications, it is approved to reduce major cardiovascular events in adults at increased risk. Your clinician reviews your risk and current treatment to determine whether this injectable therapy is appropriate. Available through Healthspan Membership with clinician-led evaluation and ongoing care. Your clinician determines whether this treatment is appropriate; a prescription is not guaranteed.
Care through Healthspan Membership
Membership is $99 per month, billed $297 every three months. Receive biomarker testing through your membership, care-team guidance, and access to prescription evaluation for cholesterol management. Your clinician reviews your history and results to determine which treatment, if any, is appropriate.